Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion

Fineline Cube Feb 28, 2026
Company Drug

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

Fineline Cube Feb 28, 2026
Company Drug

AIM Vaccine Secures NMPA Approval for mRNA Vaccine Targeting RSV

Fineline Cube Oct 30, 2024

AIM Vaccine Co., Ltd (HKG: 6660), based in China, has received clinical trial approval from...

Company Medical Device

Acotec Secures NMPA Approval for Acotrace Disposable Catheter Sheath

Fineline Cube Oct 30, 2024

Acotec Scientific Holdings Ltd (HKG: 6669), based in China, has received marketing approval from the...

Company Deals

Innovent’s Fortvita Stake Sale Sparks Controversy, Shares Plummet Nearly 13%

Fineline Cube Oct 30, 2024

Innovent Biologics, Inc. (HKG: 1801), headquartered in China, has announced a subscription agreement in which...

Company Medical Device

Sino Medical Reports Five-Year PIONEER Study Results for HT Supreme Stent System

Fineline Cube Oct 30, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), based in China, has announced the five-year follow-up...

Company Drug

Novartis Secures FDA Accelerated Approval for Scemblix in Newly Diagnosed CML Patients

Fineline Cube Oct 30, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its drug Scemblix (asciminib) has received accelerated...

Company Deals

MGI Tech Partners with OncoDNA to Enhance Precision Oncology Solutions

Fineline Cube Oct 30, 2024

MGI Tech Co., Ltd., (SHA: 688114) a China-based leader in gene sequencing, announced a strategic...

Company Medical Device

Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges

Fineline Cube Oct 30, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported its Q3 2024 financial results, revealing...

Company

BeiGene CCO Yin Min Detained Amid Investigation; Company Affirms Compliance Standards

Fineline Cube Oct 30, 2024

On October 25, Yin Min, Chief Commercial Officer of BeiGene (NASDAQ: BGNE) Greater China, was...

Company Deals

Biogen Partners with Neomorph to Develop Molecular Glue Degraders for Alzheimer’s and Rare Diseases

Fineline Cube Oct 30, 2024

U.S.-based Biogen Inc. (NASDAQ: BIIB) has announced a research collaboration with Neomorph to jointly develop...

Company Drug

Yantai Dongcheng Pharma Secures FDA Fast-Track Designation for 177Lu-LNC1004 in Thyroid Cancer

Fineline Cube Oct 30, 2024

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that it has received...

Company Drug

Sunshine Guojian Pharmaceutical Secures NMPA Approval for Clinical Trials of SSGJ-626 in Lupus Indications

Fineline Cube Oct 30, 2024

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336) has announced that it has received...

Company Drug

Zai Lab Reports Positive Phase III Results for KarXT, Showcasing Efficacy in Psychiatric Conditions

Fineline Cube Oct 30, 2024

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced encouraging topline results from...

Company Drug

Sun-Novo Pharmaceuticals Gets Green Light for CAR-T Therapy Clinical Trial in Lupus Treatment

Fineline Cube Oct 30, 2024

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) has secured approval from China’s National Medical...

Company Deals

GSK Secures Global Rights to Chimagen Biosciences’ T Cell-Engager in $850 Million Deal

Fineline Cube Oct 30, 2024

UK pharmaceutical company GSK plc (NYSE: GSK) has entered into a licensing agreement with Chimagen...

Company

Fosun Pharmaceutical Reports Q3 2024 Revenue Growth and R&D Progress

Fineline Cube Oct 30, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report...

Company

Shanghai Pharmaceuticals Reports Q3 2024 Revenue Growth, Strengthens Drug Pipeline

Fineline Cube Oct 30, 2024

China’s Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced its financial results for the...

Company Drug

Innovent Biologics’ Picankibart Shows 64.6% Skin Clearance in Phase II Psoriasis Study

Fineline Cube Oct 29, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has announced encouraging results from the multi-center, open Phase...

Company Drug

Livzon Pharmaceutical’s Leuprorelin Acetate Microspheres Passes China’s GQCE

Fineline Cube Oct 29, 2024

China’s Livzon Pharmaceutical Group Inc., (HKG: 1513, SHE: 000513) has announced that its leuprorelin acetate...

Company Drug

Xi’an Xintong Pharma’s Pradefavir Wins NMPA Nod for Chronic Hepatitis B Treatment

Fineline Cube Oct 29, 2024

The National Medical Products Administration (NMPA) has granted market approval for pradefavir, a Category 1...

Company Drug

Eli Lilly’s Mounjaro Approved in Hong Kong for Obesity and Type 2 Diabetes Treatment

Fineline Cube Oct 29, 2024

Eli Lilly & Co. (NYSE: LLY) has received market approval from Hong Kong’s Department of...

Posts pagination

1 … 238 239 240 … 628

Recent updates

  • Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion
  • Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA
  • Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer
  • Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis
  • Dupixent Wins CHMP Positive Opinion for Pediatric CSU – EU Approval Nears for Children Aged 2–11 Years
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion

Company Drug

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

Company Drug

Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer

Company Drug

Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.